NCT06593964 TACE With Thermosensitive Nanogel Versus Embosphere for HCC
| NCT ID | NCT06593964 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongda Hospital |
| Condition | Unresectable Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 188 participants |
| Start Date | 2024-09-10 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 188 participants in total. It began in 2024-09-10 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
Eligibility Criteria
Inclusion Criteria: 1. Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection, transplantation, or ablation; 2. Liver function status: Child-Pugh A or B 3. Eastern Cooperative Oncology Group score: 0-2 points; 4. With at least one measurable, unembolized liver tumor lesion (1-10 cm) ; 5. Willing to participate in this trial and sign the informed consent. Exclusion Criteria: 1. The target lesion has been embolized before or require combined with other treatment(s); 2. Diffuse or with extrahepatic metastasis; 3. Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds); 4. Severe renal dysfunctions (creatinine clearance rate \<30 ml/min); 5. Severe liver dysfunctions (alanine aminotransferase or aspartate aminotransferase exceeding the upper limit of normal by 5 times); 6. Main portal vein was completely occluded and no collateral blood supply was established; 7. With uncorrectable arteriovenous fistula or portal vein fistula; 8. Severe cachexia or hepatic encephalopathy; 9. With active infection; 10. Significant reductions in white blood cells or platelets (white blood cells\<3.0x109/L, platelets\<50x109/L) that cannot be corrected; 11. Pregnant or lactating women; 12. Difficulty in selective catheterization; 13. With the severe risk of non-target embolization; 14. Severely allergic to contrast agents or the embolic materials; 15. Participating in ongoing trial; 16. Unsuitable judged by the investigator.
Contact & Investigator
Gao-Jun Teng, M.D.
PRINCIPAL INVESTIGATOR
Zhongda Hospital
Frequently Asked Questions
Who can join the NCT06593964 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Unresectable Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06593964 currently recruiting?
Yes, NCT06593964 is actively recruiting participants. Contact the research team at llei589@126.com for enrollment information.
Where is the NCT06593964 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06593964 clinical trial?
NCT06593964 is sponsored by Zhongda Hospital. The principal investigator is Gao-Jun Teng, M.D. at Zhongda Hospital. The trial plans to enroll 188 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.